Who is sponsoring NCT03215095?

NCT03215095 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT03215095 study?

NCT03215095 studies Thyroid Cancer.

What drugs are being tested in NCT03215095?

Interventions: Durvalumab (Medi4736), Radioiodine (RAI).

What is the status of NCT03215095?

NCT03215095 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-07-08 · How we verify

Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers

NCT03215095 EARLY_PHASE1 ACTIVE_NOT_RECRUITING Results posted

The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	EARLY_PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	11
Start date	2017-07-10
Completion	2026-07

Conditions

Thyroid Cancer

Interventions

Durvalumab (Medi4736)
Radioiodine (RAI)

Primary outcomes

Number of Patients With Dose-Limiting Toxicity (DLTs) — 6 weeks beginning from the first durvalumab
Grading of DLTs will follow the guidelines provided in the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Countries

United States